Collegium Pharmaceutical (NASDAQ:COLL) Receives “Buy” Rating from HC Wainwright
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $50.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 65.84% from the stock’s current […]
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $50.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 65.84% from the stock’s current […]
